Sitagliptin - Enhancing incretin action

Campbell, Ian W. and Day, Caroline (2007). Sitagliptin - Enhancing incretin action. British Journal of Diabetes and Vascular Disease, 7 (3), pp. 134-139.


DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

Publication DOI:
Divisions: Life & Health Sciences
Uncontrolled Keywords: DPP-4,Gliptin,Incretin,Inhibitor,Sitagliptin,Type 2 diabetes,Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Full Text Link:
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Date: 2007-05-01
Authors: Campbell, Ian W.
Day, Caroline


Item under embargo.

Export / Share Citation


Additional statistics for this record